Merck ’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value.

Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

This marks Keytruda's first approval for the given indication. Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...